Compare ALG & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALG | ZYME |
|---|---|---|
| Founded | 1955 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 1993 | 2017 |
| Metric | ALG | ZYME |
|---|---|---|
| Price | $191.64 | $24.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $225.00 | $32.75 |
| AVG Volume (30 Days) | 114.5K | ★ 869.1K |
| Earning Date | 02-26-2026 | 03-04-2026 |
| Dividend Yield | ★ 0.72% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 9.64 | N/A |
| Revenue | ★ $1,615,388,000.00 | $134,481,000.00 |
| Revenue This Year | $1.26 | $64.28 |
| Revenue Next Year | $5.09 | $106.98 |
| P/E Ratio | $19.59 | ★ N/A |
| Revenue Growth | N/A | ★ 116.21 |
| 52 Week Low | $156.30 | $9.03 |
| 52 Week High | $233.29 | $28.49 |
| Indicator | ALG | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 71.58 | 48.07 |
| Support Level | $181.47 | $22.46 |
| Resistance Level | $189.18 | $25.35 |
| Average True Range (ATR) | 4.77 | 1.18 |
| MACD | 1.58 | -0.40 |
| Stochastic Oscillator | 92.99 | 43.26 |
Alamo Group Inc is engaged in the design, manufacture, and servicing of high-quality vegetation management and infrastructure maintenance equipment for governmental, industrial and agricultural use. Its products include tractor-mounted and self-propelled mowers, zero-turn mowers, agricultural implements, tree and branch chippers, forestry/wood recycling equipment, street and parking lot sweepers, leaf and debris collection equipment, truck mounted highway attenuator trucks, vacuum trucks, hydro-excavation equipment, telescopic boom excavators, and snow removal equipment. The company's reportable segments are Vegetation Management and Industrial Equipment. It generates a majority of revenue from Vegetation Management. Geographically, it generates the majority of revenue from United States.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.